{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T07:01:15Z","timestamp":1790665275263,"version":"4.1.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2021,3,18]],"date-time":"2021-03-18T00:00:00Z","timestamp":1616025600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,3,18]],"date-time":"2021-03-18T00:00:00Z","timestamp":1616025600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1007\/s40265-021-01481-6","type":"journal-article","created":{"date-parts":[[2021,3,18]],"date-time":"2021-03-18T19:12:58Z","timestamp":1616094778000},"page":"587-594","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Ravulizumab: A Review in Atypical Haemolytic Uraemic Syndrome"],"prefix":"10.1007","volume":"81","author":[{"given":"Yahiya Y.","family":"Syed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,18]]},"reference":[{"issue":"1","key":"1481_CR1","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s00467-015-3076-8","volume":"31","author":"C Loirat","year":"2016","unstructured":"Loirat C, Fakhouri F, Ariceta G, et al. An international consensus approach to the management of atypical hemolytic uremic syndrome in children. Pediatr Nephrol. 2016;31(1):15\u201339.","journal-title":"Pediatr Nephrol."},{"issue":"10095","key":"1481_CR2","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/S0140-6736(17)30062-4","volume":"390","author":"F Fakhouri","year":"2017","unstructured":"Fakhouri F, Zuber J, Fremeaux-Bacchi V, et al. Haemolytic uraemic syndrome. Lancet. 2017;390(10095):681\u201396.","journal-title":"Lancet"},{"key":"1481_CR3","doi-asserted-by":"publisher","first-page":"183","DOI":"10.2147\/IJNRD.S215370","volume":"12","author":"R Raina","year":"2019","unstructured":"Raina R, Grewal MK, Radhakrishnan Y, et al. Optimal management of atypical hemolytic uremic disease: challenges and solutions. Int J Nephrol Renovasc Dis. 2019;12:183\u2013204.","journal-title":"Int J Nephrol Renovasc Dis."},{"key":"1481_CR4","unstructured":"National Organization for Rare Disorders. Atypical hemolytic uremic syndrome. 2016. https:\/\/rarediseases.org\/. Accessed 5 Nov 2020."},{"key":"1481_CR5","doi-asserted-by":"publisher","first-page":"295","DOI":"10.2147\/CLEP.S245642","volume":"12","author":"K Yan","year":"2020","unstructured":"Yan K, Desai K, Gullapalli L, et al. Epidemiology of atypical hemolytic uremic syndrome: a systematic literature review. Clin Epidemiol. 2020;12:295\u2013305.","journal-title":"Clin Epidemiol."},{"issue":"4","key":"1481_CR6","doi-asserted-by":"publisher","first-page":"554","DOI":"10.2215\/CJN.04760512","volume":"8","author":"V Fremeaux-Bacchi","year":"2013","unstructured":"Fremeaux-Bacchi V, Fakhouri F, Garnier A, et al. Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults. Clin J Am Soc Nephrol. 2013;8(4):554\u201362.","journal-title":"Clin J Am Soc Nephrol."},{"issue":"10","key":"1481_CR7","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.2215\/CJN.02210310","volume":"5","author":"M Noris","year":"2010","unstructured":"Noris M, Caprioli J, Bresin E, et al. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol. 2010;5(10):1844\u201359.","journal-title":"Clin J Am Soc Nephrol."},{"issue":"2","key":"1481_CR8","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/j.kint.2018.02.029","volume":"94","author":"F Schaefer","year":"2018","unstructured":"Schaefer F, Ardissino G, Ariceta G, et al. Clinical and genetic predictors of atypical hemolytic uremic syndrome phenotype and outcome. Kidney Int. 2018;94(2):408\u201318.","journal-title":"Kidney Int."},{"issue":"1","key":"1481_CR9","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1111\/1744-9987.12763","volume":"23","author":"R Raina","year":"2019","unstructured":"Raina R, Krishnappa V, Blaha T, et al. Atypical hemolytic-uremic syndrome: an update on pathophysiology, diagnosis, and treatment. Ther Apher Dial. 2019;23(1):4\u201321.","journal-title":"Ther Apher Dial."},{"key":"1481_CR10","unstructured":"Alexion. SOLIRIS\u00ae (eculizumab) injection, for intravenous use: US prescribing information. 2007. https:\/\/soliris.net\/. Accessed 10 Feb 2021."},{"key":"1481_CR11","unstructured":"European Medicines Agency. Soliris 300 mg concentrate for solution for infusion: summary of product characteristics. 2007. https:\/\/www.ema.europa.eu. Accessed 10 Feb 2021."},{"issue":"1","key":"1481_CR12","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/s12882-019-1314-1","volume":"20","author":"J Menne","year":"2019","unstructured":"Menne J, Delmas Y, Fakhouri F, et al. Outcomes in patients with atypical hemolytic uremic syndrome treated with eculizumab in a long-term observational study. BMC Nephrol. 2019;20(1):125.","journal-title":"BMC Nephrol."},{"key":"1481_CR13","unstructured":"European Medicines Agency. Ultomiris 300 mg concentrate for solution for infusion: summary of product characteristics. 2020. https:\/\/www.ema.europa.eu\/. Accessed 9 Nov 2020."},{"key":"1481_CR14","unstructured":"Alexion. Ultomiris\u00ae (ravulizumab-cwvz) injection, for intravenous use: US prescribing information. 2019. https:\/\/www.ultomiris.com\/. Accessed 9 Nov 2020."},{"key":"1481_CR15","unstructured":"Alexion. Ultomiris\u24c7 for drip infusion 300 mg: Japanese prescribing information. 2019. https:\/\/www.pmda.go.jp\/PmdaSearch\/iyakuDetail\/870056_6399427A1027_1_03#HDR_Warnings. Accessed 15 Feb 2021."},{"key":"1481_CR16","unstructured":"R\u00f6th A, Hill A, Aguzzi R, et al. An interim analysis of a phase 2 study evaluating the efficacy, safety, and pharmacokinetics of intravenous ravulizumab 100 mg\/mL formulation in patients with paroxysmal nocturnal hemoglobinuria [abstract no. EP862 plus poster]. In: 25th Annual Congress of the European Hematology Association. 2020."},{"key":"1481_CR17","unstructured":"European Medicines Agency. Ultomiris: assessment report. 2020. https:\/\/www.ema.europa.eu. Accessed 9 Nov 2020."},{"key":"1481_CR18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0195909","author":"D Sheridan","year":"2018","unstructured":"Sheridan D, Yu ZX, Zhang Y, et al. Design and preclinical characterization of ALXN1210: a novel anti-C5 antibody with extended duration of action. PLoS ONE. 2018. https:\/\/doi.org\/10.1371\/journal.pone.0195909.","journal-title":"PLoS ONE"},{"issue":"6","key":"1481_CR19","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1016\/j.kint.2020.01.035","volume":"97","author":"E Rondeau","year":"2020","unstructured":"Rondeau E, Scully M, Ariceta G, et al. The long-acting C5 inhibitor, ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome na\u00efve to complement inhibitor treatment. Kidney Int. 2020;97(6):1287\u201396.","journal-title":"Kidney Int."},{"key":"1481_CR20","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-020-04774-2","author":"K Tanaka","year":"2020","unstructured":"Tanaka K, Adams B, Aris AM, et al. The long-acting C5 inhibitor, ravulizumab, is efficacious and safe in pediatric patients with atypical hemolytic uremic syndrome previously treated with eculizumab. Ped Neph. 2020. https:\/\/doi.org\/10.1007\/s00467-020-04774-2.","journal-title":"Ped Neph."},{"key":"1481_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2020.10.046","author":"G Ariceta","year":"2020","unstructured":"Ariceta G, Dixon BP, Kim SH, et al. The long-acting C5 inhibitor, ravulizumab, is effective and safe in pediatric patients with atypical hemolytic uremic syndrome naive to complement inhibitor treatment. Kidney Int. 2020. https:\/\/doi.org\/10.1016\/j.kint.2020.10.046.","journal-title":"Kidney Int."},{"key":"1481_CR22","doi-asserted-by":"crossref","unstructured":"G\u00e4ckler A, Dobronravov V, La Manna G, et al. Efficacy and safety of the long-acting C5 inhibitor ravulizumab in patients with postpartum atypical haemolytic uraemic syndrome [abstract no. MO020]. Nephrol Dial Transplant. 2020;35(Suppl 3).","DOI":"10.1093\/ndt\/gfaa140.MO020"},{"key":"1481_CR23","doi-asserted-by":"crossref","unstructured":"Barbour T, Scully M, Ariceta G, et al. One-year efficacy and safety of the long acting C5 inhibitor ravulizumab for the treatment of atypical haemolytic uraemic syndrome (aHUS) in adults [abstract no. SO054]. Nephrol Dial Transplant. 2020;35(Suppl 3).","DOI":"10.1093\/ndt\/gfaa139.SO054"},{"issue":"12","key":"1481_CR24","doi-asserted-by":"publisher","first-page":"2449","DOI":"10.1681\/ASN.2019040331","volume":"30","author":"J Zuber","year":"2019","unstructured":"Zuber J, Frimat M, Caillard S, et al. Use of highly individualized complement blockade has revolutionized clinical outcomes after kidney transplantation and renal epidemiology of atypical hemolytic uremic syndrome. J Am Soc Nephrol. 2019;30(12):2449\u201363.","journal-title":"J Am Soc Nephrol."},{"issue":"1","key":"1481_CR25","doi-asserted-by":"publisher","first-page":"98","DOI":"10.4161\/viru.26515","volume":"5","author":"LA Lewis","year":"2014","unstructured":"Lewis LA, Ram S. Meningococcal disease and the complement system. Virulence. 2014;5(1):98\u2013126.","journal-title":"Virulence."},{"key":"1481_CR26","doi-asserted-by":"crossref","unstructured":"Rondeau E, Hatswell AJ, Cataland S. Comparative efficacy of ravulizumab and eculizumab in the treatment of atypical hemolytic uremic syndrome: an indirect comparison using clinical trial data [abstract no. PO1851]. In: American Society of Nephrology Annual Meeting. 2020.","DOI":"10.1681\/ASN.20203110S1576d"},{"key":"1481_CR27","doi-asserted-by":"crossref","unstructured":"Levy A, Chen P, Tomazos I. Ravulizumab reduces productivity losses versus eculizumab for treating atypical hemolytic uremic syndrome: a cost consequence analysis in four countries. In: ISPOR Europe. 2020.","DOI":"10.1016\/j.jval.2020.08.1769"},{"issue":"Suppl. 1","key":"1481_CR28","doi-asserted-by":"publisher","first-page":"S335","DOI":"10.1016\/j.jval.2020.04.1264","volume":"23","author":"Y Wang","year":"2020","unstructured":"Wang Y, Johnston K, Popoff E, et al. A US cost-minimization model comparing lifetime per-patient costs for ravulizumab and eculizumab for the treatment of atypical hemolytic uremic syndrome [abstract no. PRO36]. Value Health. 2020;23(Suppl. 1):S335.","journal-title":"Value Health."},{"key":"1481_CR29","doi-asserted-by":"crossref","unstructured":"Williams K, Aggio D, Chen P, et al. Utility values associated with treatment attributes for atypical hemolytic uremic syndrome: a discrete choice experiment in five countries. In: ISPOR Europe. 2020.","DOI":"10.1007\/s40273-021-01059-w"}],"updated-by":[{"DOI":"10.1007\/s40265-021-01517-x","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2021,4,19]],"date-time":"2021-04-19T00:00:00Z","timestamp":1618790400000}},{"DOI":"10.1007\/s40265-021-01563-5","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2021,7,10]],"date-time":"2021-07-10T00:00:00Z","timestamp":1625875200000}}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-021-01481-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-021-01481-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-021-01481-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,26]],"date-time":"2024-08-26T08:42:50Z","timestamp":1724661770000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-021-01481-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,18]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["1481"],"URL":"https:\/\/doi.org\/10.1007\/s40265-021-01481-6","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,18]]},"assertion":[{"value":"18 March 2021","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 December 2021","order":2,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":3,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Video inclusion after abstract","order":4,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2021","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s40265-021-01563-5","URL":"https:\/\/doi.org\/10.1007\/s40265-021-01563-5","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 April 2021","order":9,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":10,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":11,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s40265-021-01517-x","URL":"https:\/\/doi.org\/10.1007\/s40265-021-01517-x","order":12,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Yahiya Y. Syed is a salaried employee of Adis International Ltd\/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval, consent to participate, consent to publish, availability of data and material, code availability"}}]}}